This week’s medical roundup highlights five notable advances across oncology, diagnostics, surgery and device design. A bispecific antibody called tarlatamab showed a survival benefit over standard chemotherapy in a subset of small cell lung cancer and could move from accelerated to full approval if phase 3 data are confirmed. In diagnostics, PanDerm — a universal dermatology AI — improved clinicians’ accuracy across photos, dermoscopy and pathology but still needs broader validation. A randomized trial found robotic rectal cancer surgery reduced recurrence and long‑term functional problems versus conventional keyhole surgery. Early gastric cancer trials show durvalumab may boost responses, and a 'milli‑spinner' device can shrink tough clots in preclinical models. Each advance is promising but most require more testing, wider validation and implementation work before becoming standard of care.
Tarlatamab beats chemo for a subset of small cell lung cancers
Small cell lung cancer (SCLC) is typically treated with platinum‑based chemotherapy, but resistance and toxicity limit long‑term outcomes. Tarlatamab is a bispecific antibody that recruits T cells directly to tumor cells by binding DLL3, a protein found on roughly 90% of SCLC tumors. In a pivotal phase 3 trial, tarlatamab improved overall survival compared with physician's choice of chemotherapy and produced fewer grade 3 adverse events, though it introduced cytokine release syndrome as a new risk. The drug already has accelerated approval as second‑line therapy after platinum chemotherapy; these phase 3 results could support conversion to full approval and are prompting trials testing tarlatamab in first‑line combinations.
PanDerm: an AI that helps dermatologists make more accurate diagnoses
PanDerm is a generalized dermatology artificial intelligence designed to analyze ordinary clinical photos, dermoscopy images, total‑body photography and pathology slides. In validation studies it raised diagnostic accuracy when used as an assistive tool for both generalists and dermatologists, suggesting potential to speed triage, reduce missed diagnoses and improve referral accuracy. However, the model is currently validated on only about 200 of the more than 1,000 recognized skin conditions, so coverage gaps remain. Before routine clinical use we need expanded disease scope, prospective real‑world trials, and explicit equity testing across skin tones and devices to ensure reliable performance for diverse populations.
Robotic surgery outperforms keyhole surgery in rectal cancer
A randomized controlled trial compared robotic‑assisted versus conventional laparoscopic (keyhole) surgery for mid‑to‑low rectal cancer. Robotic systems provide wristed instruments and greater angulation, which ease dissection inside the narrow pelvis. The trial reported that robotic surgery reduced the risk of cancer recurrence and resulted in fewer long‑term bladder, sexual and bowel dysfunctions compared with standard keyhole techniques. All patients were enrolled in one country (China), so international replication is needed to confirm generalizability. Broader adoption will also require expanded surgical training, infrastructure investment and cost‑effectiveness analyses, but the findings point to real oncologic and functional benefits when robotics are available.
Durvalumab may improve outcomes in resectable gastric cancer
Resectable gastric cancer is usually managed with perioperative chemotherapy and surgery, but relapse risk remains substantial. A phase 3 trial tested whether adding durvalumab, an anti‑PD‑L1 immunotherapy, to the preoperative regimen could improve outcomes. Durvalumab increased disease‑free survival and tripled complete pathological response rates without delaying surgery. Overall survival data are not yet mature, and immune‑mediated adverse events approximately doubled, although overall side‑effect profiles were similar. Important questions remain about whether both pre‑ and post‑operative dosing are necessary and which patients benefit most. Follow‑up studies will define optimal timing, duration and patient selection.
A 'milli‑spinner' could upgrade how we remove tough clots
Mechanical thrombectomy is life‑saving for ischemic stroke and other clot‑related emergencies, but current aspiration and stent‑retriever tools fail on large, tough thrombi in up to about 30% of cases. The experimental 'milli‑spinner' device uses rapid rotation to compress and shear stubborn clots down to roughly 5% of their original volume, allowing removal by aspiration. In bench studies and pig artery models it outperformed standard thrombectomy techniques. The device has not yet been tested in intracranial or pulmonary vessels or in humans; next steps include testing in brain‑relevant vasculature, assessing embolic safety and deliverability, and early human trials if preclinical safety is confirmed.
